SCHEMBL1128375

SCHEMBL1128375

CCOC(=O)c1c(O)n2ccccc2c(Cc2cccc(OC)c2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.48
ALOX5 P09917 1/20 0.48
IDH1 O75874 2/20 0.46
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
GAA P10253 2/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
POLB P06746 2/20 0.43
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
IDO1 P14902 1/20 0.42
MAPK1 P28482 1/20 0.42
HBB P68871 1/20 0.42
HIF1A Q16665 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 2/20 0.42
VKORC1 Q9BQB6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13658301 0.89 KDM4E (0.50) ALOX5ALDH1A1KDM4EGAAGLA
SCHEMBL1127254 0.88 ALDH1A1 (0.48) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL4289628 0.83 KDM4E (0.44) PTGESALOX5ALDH1A1KDM4EGAA
SCHEMBL1128142 0.83 KDM4E (0.46) PTGESALOX5ALDH1A1KDM4EGAA
SCHEMBL1127987 0.82 ALDH1A1 (0.49) PTGESALOX5ALDH1A1KDM4EGAA
SCHEMBL13658303 0.81 ALDH1A1 (0.44) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL1127411 0.80 ALDH1A1 (0.43) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL13662302 0.80 IDH1 (0.47) IDH1ALDH1A1HPGDPOLBTP53
SCHEMBL1127428 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL1127429 0.78 ALDH1A1 (0.45) ALDH1A1KDM4EGAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF PTGES 2392/4885ALOX5 4075/4885IDH1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.